HER2
Assets acting on this target.
- Class
- HER2-directed therapy
- Pathway
- HER2 signaling blockade / HER2-directed targeting in HER2-expressing tumors
HER2 (human epidermal growth factor receptor 2) is a receptor tyrosine kinase belonging to the ErbB/HER family of cell-surface growth factor receptors. In normal tissue it helps regulate cell growth and division, but in a subset of cancers (most notably certain breast and gastric tumors) the HER2 gene is amplified, causing the receptor to be overexpressed. This excess HER2 dimerizes readily with itself or other HER family members, continuously activating downstream growth pathways (including RAS-MAPK and PI3K-AKT) independent of normal growth signals, driving uncontrolled proliferation and survival of tumor cells. Because HER2 overexpression is confined largely to tumor cells relative to normal tissue, it serves as a rational target for selective anticancer therapy. Several distinct strategies exploit this: monoclonal and bispecific antibodies bind the extracellular domain to block receptor dimerization and flag cells for immune destruction; small-molecule tyrosine kinase inhibitors block the intracellular kinase directly, which can also reach the brain, relevant for metastatic disease; antibody-drug conjugates use HER2 binding to deliver cytotoxic payloads directly into tumor cells; and radiopharmaceuticals use HER2 binding to localize radiation. This mechanism broadly matters across HER2-driven breast, gastric, and other epithelial cancers.
By indication
Related mechanisms
HER2 drugs compared
17 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| margetuximabMargenza | TerSera Therapeutics LLC | monoclonal antibody | Approved | Approved in Breast Cancer; Approved in HER2-Positive Breast Cancer |
| Trastuzumab Deruxtecan | AstraZeneca, Daiichi Sankyo | antibody-drug conjugate | Approved | Approved in Breast Cancer; Approved in HER2-Positive Breast Cancer; Approved in HR+/HER2- Metastatic Breast Cancer; Approved in Non-Small Cell Lung Cancer |
| Tucatinib | Merck & Co., Pfizer | small molecule | Approved | Approved in Advanced Metastatic Colorectal Cancer; Approved in Breast Cancer; Approved in Colorectal Cancer; Approved in HER2-Positive Breast Cancer; Approved in Metastatic Colorectal Cancer; Phase 2 in Non-Small Cell Lung Cancer |
| Zanidatamab | BeOne Medicines, Jazz Pharmaceuticals, Zymeworks | bispecific antibody | Approved | Approved in Biliary Tract Cancer; Approved in Gastric Cancer; Phase 3 in HER2-Positive Breast Cancer; Phase 2 in Non-Small Cell Lung Cancer |
| Disitamab Vedotin | Pfizer, RemeGen Co., Ltd. | antibody-drug conjugate | Phase 3 | Phase 3 in Gastric Cancer; Phase 3 in HR+/HER2- Metastatic Breast Cancer; Phase 3 in Urothelial Carcinoma; Phase 2/3 in HER2-Positive Breast Cancer; Phase 2 in Non-Small Cell Lung Cancer |
| Trastuzumab brengitecan | Sichuan Baili Pharmaceutical | antibody-drug conjugate | Phase 3 | Phase 3 in Biliary Tract Cancer; Phase 3 in Colorectal Cancer; Phase 3 in HER2-Positive Breast Cancer; Phase 3 in Non-Small Cell Lung Cancer; Phase 3 in Ovarian Cancer; Phase 3 in Urothelial Carcinoma |
| Trastuzumab pamirtecan | BioNTech, DualityBio Inc. | antibody-drug conjugate | Phase 3 | Phase 3 in Endometrial Cancer; Phase 3 in HER2-Positive Breast Cancer; Phase 3 in HR+/HER2- Metastatic Breast Cancer |
| Trastuzumab rezetecan | Glenmark Pharmaceuticals Ltd., Jiangsu Hengrui Pharmaceuticals | antibody-drug conjugate | Phase 3 | Phase 3 in Breast Cancer; Phase 3 in Colorectal Cancer; Phase 3 in Gastric Cancer; Phase 3 in HER2-Positive Breast Cancer; Phase 3 in HR+/HER2- Metastatic Breast Cancer; Phase 3 in Non-Small Cell Lung Cancer; Phase 3 in Ovarian Cancer |
| Bizrolertinib | Roche | small molecule | Phase 2/3 | Phase 2/3 in HER2-Positive Breast Cancer |
| HRS-4508 | Jiangsu Hengrui Pharmaceuticals | small molecule | Phase 2 | Phase 2 in Non-Small Cell Lung Cancer |
| 177Lu-DWJ155 | Novartis | radiopharmaceutical | Phase 1 | Phase 1 in Non-Small Cell Lung Cancer |
| BL-M17D1 | SystImmune | antibody-drug conjugate | Phase 1 | Phase 1 in Non-Small Cell Lung Cancer |
| KJ015 | Shanghai Bao Pharmaceuticals Co., Ltd. | bispecific antibody (biparatopic) | Phase 1 | Phase 1 in Non-Small Cell Lung Cancer |
| MT-304 | CREATE Medicines | mRNA (in vivo CAR, LNP) | Phase 1 | Not recorded |
| NVL-330 | GlaxoSmithKline, Nuvalent, Inc. | small molecule | Phase 1 | Phase 1 in HER2-Mutant Non-Small Cell Lung Cancer; Phase 1 in Non-Small Cell Lung Cancer |
| RAD202 | Radiopharm Theranostics, Ltd | radiopharmaceutical | Phase 1 | Phase 1 in HER2-Positive Advanced Solid Tumors |
| GSK6855547 | GlaxoSmithKline | small molecule | Stage not recorded | Not recorded |